Oramed Pharmaceuticals Issues Letter to Shareholders
Oramed Pharmaceuticals Inc. (ORMP)
Last oramed pharmaceuticals inc. earnings: 4/6 04:46 pm
Check Earnings Report
US:NASDAQ Investor Relations:
oramed.com/investors
Company Research
Source: PR Newswire
Key Highlights – expected completion in YR 2025:OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials.Distribution of majority of Oramed's holding in OraTech to Oramed shareholders via dividend planned to coincide with OraTech's public listing.Cash dividend planned (~$0.25 per share).Marketing Authorization Application has been submitted by HTIT, and commercialization preparations are underway for oral insulin capsule. OraTech expected to receive royalties from sales in China.Oramed to receive royalty streams over the next decade from multiple Scilex products including $400,000 due for Q4 2024 sales.NEW YORK, March 4, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a letter to its shareholders from its President and Chief Executive Officer Nadav Kidron.Dear Shareholde
Show less
Read more
Impact Snapshot
Event Time:
ORMP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORMP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORMP alerts
High impacting Oramed Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ORMP
News
- Oramed Pharmaceuticals (NASDAQ:ORMP) had its "hold (c)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Oramed Reports Fiscal Third Quarter 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Oramed Reports Fiscal Third Quarter 2025 Financial ResultsPR Newswire
- ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTSPR Newswire
- Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives [Yahoo! Finance]Yahoo! Finance
ORMP
Earnings
- 11/13/25 - Beat
ORMP
Sec Filings
- 11/17/25 - Form 8-K
- 11/17/25 - Form 8-A12B
- 11/17/25 - Form 8-K
- ORMP's page on the SEC website